Aspirin intake and head and neck cancer: A pooled analysis within the INHANCE consortium. Other Scholarly Work

Sassano, Michele, Taborelli, Martina, Boccia, Stefania et al. (2024). Aspirin intake and head and neck cancer: A pooled analysis within the INHANCE consortium. . HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 46(4), 926-935. 10.1002/hed.27638

cited authors

  • Sassano, Michele; Taborelli, Martina; Boccia, Stefania; Cadoni, Gabriella; La Vecchia, Carlo; Garavello, Werner; Lazarus, Philip; Lee, Yuan-Chin Amy; Hashibe, Mia; Boffetta, Paolo



  • Background

    Aspirin intake might be inversely associated with head and neck cancer (HNC). Thus, we investigated this relationship within the International Head and Neck Cancer Epidemiology (INHANCE) consortium.


    Four case-control studies within the INHANCE consortium were included (2024 cases, 4196 controls). Study-specific odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression and subsequently pooled with DerSimonian-Laird random-effects model. Nonlinearity of the relationship between duration of intake and HNC was modeled with fractional polynomials.


    Aspirin was inversely associated with HNC overall (OR = 0.48; 95% CI: 0.26, 0.91). Results for laryngeal cancer were similar (OR = 0.54; 95% CI: 0.30, 0.96). Analysis on duration of intake confirmed findings for HNC overall, showing also inverse associations for oropharyngeal and laryngeal cancer.


    This study suggests that aspirin intake may reduce the risk of HNC, driven mainly by decreases in risk for laryngeal and oropharyngeal cancer.

publication date

  • April 1, 2024


  • Case-Control Studies
  • Head and Neck Neoplasms
  • Humans
  • Laryngeal Neoplasms
  • Oropharyngeal Neoplasms
  • Risk Factors

Digital Object Identifier (DOI)


  • Print-Electronic

start page

  • 926

end page

  • 935


  • 46


  • 4